Abstract The complex life cycle and immunopathological features underpinning the interaction of Leishmania parasites and their mammalian hosts poses frequent poorly explored and inconclusively resolved questions. The altered nociceptive signals over the course of leishmaniasis remain an intriguing issue for nociceptive and parasitology researchers. Experimental investigations have utilized behavioral, morphological, and neuro-immune approaches in the study of experimental cutaneous leishmaniasis (CL). The data generated indicates new venues for the study of the pathological characteristics of nociceptive processing in this parasitic disease. Leishmania-induced pain may be easily observed in mice and rats. However, nociceptive data is more complex in human investigations, including the occurrence of painless lesions in mucocutaneous and cutaneous leishmaniasis. Data from recent decades indicate that humans can also be affected by pain-related symptoms, often distinct from the region of body infection. The molecular and cellular mechanisms underlying such variable nociceptive states in humans during the course of leishmaniasis are an active area of research. The present article reviews nociception in leishmaniasis, including in experimental models of CL and clinical reports.
Introduction
The study of the tropical parasitic disease, leishmaniasis, is relatively neglected. Leishmania protozoa is propagated and maintained by a complex life cycle between the parasite, vectors, and mammalian hosts, including humans, dogs, or rodents (World Health Organization 2016; Karimkhani et al. 2016) . According to the WHO, over 98 countries and territories are endemic for leishmaniasis. Estimates indicate that 0.2-0.4 million new cases of visceral leishmaniasis and 0.7-1.3 million new cases of cutaneous leishmaniasis (CL) are diagnosed each year worldwide. The vast majority of cases occur in countries such as Algeria, Bangladesh, Bolivia, Brazil, Colombia, Costa Rica, Ethiopia, India, Iran, Nepal, Peru, South Sudan, Sudan, and Syria (World Health Organization 2016; Karimkhani et al., 2016; Salam et al. 2014) . It is not unlikely that these numbers are underestimated due to misdiagnosis and discrepancies in reporting guidelines. Indeed, the diagnosis of leishmaniasis represents a challenge for medicine, as its symptoms resemble other infectious and/or malignant diseases both in cutaneous tissue and internal organs (Handler et al. 2015a; Karimkhani et al. 2016) . The three main forms of leishmaniasis are visceral (also described as Khala-azar, which represents the most aggressive form of the infection), cutaneous (the most common), and mucocutaneous (World Health Organization 2016) .
More than 30 species of the unicellular protozoan parasites of the Leishmania genus (Trypanosomatida; Trypanosomatidae) can cause leishmaniasis in mammalian hosts. Of note, 20 species are pathogenic to human beings (Akhoundi et al. 2016; Gramiccia and Gradoni 2005; Handler et al. 2015b; Kevric et al. 2015) . Table 1 lists the species of Leishmania and Viannia subgenus (Euleishmania phylogenetic lineage), including the majority of species capable of causing disease in humans (Akhoundi et al. 2016; Gramiccia and Gradoni 2005; Handler et al. 2015b; Kevric et al. 2015) . Parasites are transmitted through the bites of the infected female phlebotomine sandfly vectors (Phlebotomus in the Old World and Lutzomyia in the New World) (Handler et al. 2015a) . The complex life cycle of the Leishmania species begins with the flagellated motile extracellular procyclic promastigotes in the intestine of vectors, where they multiply through binary division. The parasites undergo metacyclogenesis becoming non-dividing metacyclic promastigotes, a mammal-infective stage, and then migrate to the salivary glands of the vectors. Through regurgitation, female sandflies introduce parasites together with immunomodulatory factors and other various salivary components during the feeding in the exposed areas of the skin of the hosts. Such parasites and other factors are taken up by phagocytes, such as neutrophils, dendritic cells and, especially, macrophages in dermal tissue. The efferocytosis of infected apoptotic neutrophils by macrophages is also a root of parasite cellular invasion (Handler et al. 2015a; Kaye and Scott 2011; Ribeiro-Gomes and Sacks 2012) . Inside macrophages, there is a transformation into another parasitic stage, amastigotes (non-flagellated form), where proliferation occurs. Proliferation may also occur in other cells of different tissues, such as the lymph nodes and liver (Barsky et al. 1978; Reithinger et al. 2007) . The cycle restarts when female sandflies ingest infected cells during the feeding on the infected host. Inside the vectors, parasites become promastigotes as soon as they reach the hindgut or midgut (depending on the subgenus of Leishmania spp.), where they multiply to migrate again to the salivary glands of the vectors, thereby perpetuating its life cycle (Handler et al. 2015a; Kaye and Scott 2011; Ribeiro-Gomes and Sacks 2012) . Figure 1 summarizes the life cycle of the infective agent in anthroponotic leishmaniasis.
Although progress has been achieved in recent decades as to the immunopathology and molecular biology of leishmaniasis, as well as pathogenicity of Leishmania spp. (Cunha et al. 2016; Gollob et al. 2014; Kevric et al. 2015; McConville 2016; Mukherjee et al. 2015; Novais et al. 2015; Ortiz et al. 2016) , the nociceptive pathways pertaining to leishmaniasis have still to be fully explored. Data in humans indicate that ulcerative skin lesions of leishmaniasis are painless (González et al. 2008; Handler et al. 2015a; Kelly et al. 2012; Morris-Jones and Weber 2004) , perhaps surprising given the severity of lesions observed in patients diagnosed with cutaneous or mucocutaneous leishmaniasis. It is possible that leishmaniasis and/or Leishmania spp. may modulate pain perception and nociceptive transmission during the course of disease (Cangussu et al. 2013 ). This clinical picture resembles the characteristics of other serious cutaneous infectious diseases, such as hanseniasis, where a peripheral neural involvement is well established (Satti et al. 1989) . Symptoms of leprous neuropathy may vary and usually include anesthetic, painless, and non-itchy skin patches together with the development of sensory symptoms, such as attenuated or complete loss of sensation, paresthesia of affected nerves, and neuralgic pain in cases where the damaged nerves are drawn or struck (Scollard et al. 2 0 0 6 ) . T h e i n f e c t i o u s a g e n t i n h a n s e n i a s i s , Mycobacterium leprae, is commonly found in different cell lineages such as Schwann cells, macrophages, fibroblasts, and perineural cells. These cells surround the affected nerves and produce inflammation that affects epineurium and perineurium leading to abnormalities of nerve conduction and, consequently, sensory neuropathy (Chopra et al. 1983; Jardim et al. 2015; Thacker et al. 1996) . Regarding Leishmania spp., it is still unknown as to whether the parasite can cause direct damage to the cutaneous nerves or dysfunctions in nerve conduction. Peripheral neural involvement is indicated by data showing the presence of massive inflammatory infiltrates indicative of neuritis, and parasites inside the nerves of both humans and mice infected with CL (Cangussu et al. 2013; Elhassan et al. 1992; Kanaan et al. 2000; Kibbi et al. 1996; Kubba et al. 1987; Satti et al. 1989) . Such data highlight the requirement of future studies in this area.
Such pathophysiological processes and varying presentations also highlight the need for an accurate clinical and histopathological evaluation of the patients suspected of CL, which should also help to minimize misdiagnosis. Although some clinical studies have shown the absence of painful lesions in patients (González et al. 2008; Handler et al. 2015a; Kelly et al. 2012; Kochar et al. 2006; Kroidl et al. 2014; Morris-Jones and Weber 2004) , there is growing body of evidence highlighting the presence of pain-related symptoms in individuals with the three forms of leishmaniasis, independent of patient age or body region affected. Pain may be located in the primary foci of the infection, as can occur in ulcerative lesions, or in distant tissues and organs (el-Safi et al. 1991; Gontijo et al. 2002; Kubba et al. 1987; Ondriska et al. 2015; Punda-Polic et al. 1997; Satti et al. 1989; Weller et al. 2005; Wind et al. 2014) . Interestingly, nociceptive behaviors are evident in animals infected with Leishmania versus non-infected controls (Cangussu et al. 2013; Haber et al. 2009; Kanaan et al. 2000; Kanaan et al. 2002; Karam et al. 2011; Karam et al. 2007; Karam et al. 2006; Karam et al. 2013; Karam et al. 2016; Satti et al. 1989) . Below, the available data regarding pain perception in clinical cases and experimental leishmaniasis are reviewed, in order to better clarify the mechanisms that drive alterations in nociceptive processes, both in humans and animals. By integrating such data, this review provides a novel perspective on pain-related changes in parasitic infection, as well as a pathway for future research of the complex pathophysiology of nociceptive processing in leishmaniasis.
Leishmania-induced pain in animal models
There is evidence of nociceptive responses induced by Leishmania sp. infections in animals, particularly rodents (Cangussu et al. 2013; Haber et al. 2009; Kanaan et al. 2000; Kanaan et al. 2002; Karam et al. 2011; Karam et al. 2007; Karam et al. 2006; Karam et al. 2013; Karam et al. 2016; Satti et al. 1989) . Although varied concentrations of Leishmania sp. (1 × 10 3 to 1.5 × 10 7 ) have been used in these studies, all used only Leishmania major. These experimental models of leishmaniasis were used to primarily evaluate the relationships among hyperalgesia (exaggerated pain in response to noxious stimuli), neural involvement in cutaneous tissue, and the role of chemical mediators such as cytokines and growth factors (Cangussu et al. 2013; Haber et al. 2009; Kanaan et al. 2000; Kanaan et al. 2002; Karam et al. 2011; Karam et al. 2007; Karam et al. 2006; Karam et al. 2013; Karam et al. 2016) . Most of these works used the same strain of mice (BALB/c) and the same species of Leishmania, however, these studies demonstrated different responses regarding the role of cytokines in L. major-induced pain (Cangussu et al. 2013; Haber et al. 2009; Kanaan et al. 2000; Kanaan et al. 2002; Karam et al. 2011; Karam et al. 2007; Karam et al. 2006; Karam et al. 2013; Karam et al. 2016; Satti et al. 1989 ). This can be attributed to the different L. major Fig. 1 Life cycle of Leishmania parasite, the causative agent of leishmaniasis. 1 During the blood meal in the exposed areas of human body, female sandflies injects promastigotes in their infective stage into the skin; 2 The parasites are captured by phagocytes in dermal tissue, initially by short-lived neutrophils (the first leukocyte recruited to the bite site that subsequently enter into apoptosis) and subsequently also by macrophages; 3 In addition to phagocytized parasites, macrophages also phagocytize infected apoptotic neutrophils; 4 Inside the macrophages, promastigotes establish an intracellular residence and transform into aflagellate amastigotes, where they multiply, and are released upon cell lysis, when too many amastigotes are present in the phagolysosome, resulting in reinfection of other cells; 5 The cycle is completed when other sandfly ingest infected phagocytes during the blood meal; 6 Inside the vectors, amastigotes are converted into promastigotes in hindgut/midgut; 7 At this site, parasites proliferate and differentiate into infective promastigotes and migrate to the salivary glands of the sandfly and perpetuate its life cycle concentration used, which suggests that the parasite burden may affect the nociceptive response. Kanaan and coworkers demonstrated the production of interleukin (IL)-1β and nerve growth factor (NGF), but not tumor necrosis factor (TNF)-α, in L. major (3 × 10 5 )-induced hyperalgesia in a chronic mouse model of CL (8 weeks post-infection), using hot plate and tail flick tests. This study observed L. major-induced hyperalgesia and the up-regulation of IL-1β and NGF, which were inhibited by chronic treatment with thymulin, the thymic hormone with immunomodulatory and anti-inflammatory properties (Kanaan et al. 2000; Kanaan et al. 2002; SafiehGarabedian et al. 1996a; Safieh-Garabedian et al. 1996b ). The authors also observed neuritis affecting cutaneous nerves as well as peripheral edema in the infected paw, which were associated with increased pain-related symptoms (Kanaan et al. 2000) .
In one study, BALB/c and C57BL/6 (mouse strains susceptible and resistant to leishmaniasis, respectively) mice were infected by intradermal injection with L. major (1 × 10 3 ) in the ear to evaluate the interaction among neurons, cytokine profile, and nociception over 12 weeks. Unlike other studies using hot plate and tail flick tests, the intensity of hyperalgesia was evaluated using a thermoalgesimeter test, which measured heat-evoked nociception-related behavior in the murine ear. The authors observed a different pattern of response regarding neural damage, cytokine profile, and behavioral tests in these two strains (Cangussu et al. 2013) . At 9 weeks postinfection, BALB/c mice presented with severe lesions. At this time point, BALB/c mice showed hypoalgesia and no nerve damage, as well as reduced levels of the anti-hyperalgesic cytokine, IL-10, and slightly increased levels of the prohyperalgesic cytokine IL-1β at the earlier 2-week time-point. In contrast, C57BL/6 mice demonstrated an early hyperalgesia at week two, which returned to the levels of the control group within 5 weeks. Concomitantly, these researchers observed a decrease in nerve density suggesting nerve injury, which was associated with local increases in the production of pro-hyperalgesic cytokines IL-6, TNF-α, keratinocyte-derived cytokine (KC)/chemokine (C-X-C motif) ligand 1 (CXCL1), and anti-hyperalgesic cytokine IL-10. Given that the aforementioned pro-inflammatory cytokines are well-known mediators of inflammatory hyperalgesia Verri et al. 2006) , it is possible that they have a role in the nociception-related behavior observed in C57BL/6 mice (Cangussu et al. 2013) . Moreover, the increased IL-10 levels at the same period may represent an endogenous anti-hyperalgesic response profile to limit the hyperalgesia and inflammation induced by TNF-α, IL-6, and KC/CXCL1 (Borghi et al. 2015; Cangussu et al. 2013; Poole et al. 1995; Verri et al. 2006 ). This evidence of higher pain threshold in both strains in the last weeks of the investigation may have parallels with the painless ulcers that are evident in clinical advanced destructive lesions during the later stages of leishmaniasis (Cangussu et al. 2013) . The involvement of cutaneous nerves, and consequent peripheral neuritis, shown in the above studies, corroborate previous reports demonstrating infiltrating leukocytes as well as parasitic burden in cutaneous nerves of patients infected by L. major and Leishmania donovani (Elhassan et al. 1992; Kibbi et al. 1996; Kubba et al. 1987; Satti et al. 1989) . Further, more than 65% of infected mice, to some degree, presented with a cutaneous neural involvement in an experimental model of CL (L. major, 1.5 × 10 7 ) (Satti et al. 1989 ). The neural involvement shown in these studies was associated with nerve destruction (Cangussu et al. 2013; Kubba et al. 1987; Satti et al. 1989) , suggesting that Leishmania spp. may have the ability to modify the physiological state of the cutaneous nerves in the ulcerative lesion, either by direct damage or through the induction of changes in electrophysiological properties of sensory neurons. Another possibility is the involvement of satellite lymphatics, leading to nerve compression (Llanos-Cuentas et al. 2013) , which may be important in the study of Leishmania-induced pain. Recent work showed that Mycobacterium ulcerans, the causative agent of a Buruli ulcer, has the ability to induce analgesia in ulcerative skin lesions, therefore, indicating that other infectious agents may also parallel the clinical presentations of CL lesions. This analgesia arises from secreted mycolactone, which signals through the angiotensin type II receptors in skin cells, and triggers an intracellular cascade leading to potassiumdependent nociceptor neuron hyperpolarization, and consequently analgesia (Guenin-Mace et al. 2015; Marion et al. 2014) .
Other type of bacteria, such as Staphylococcus aureus, directly activate nociceptor neurons inducing calcium influx and consequently action potentials in these cells, through a mechanism involving N-formylated peptides and the pore-forming toxin α-hemolysin (Chiu et al. 2013) . It is therefore possible that the particular biological and structural characteristics of each micro-organism determine whether it may, or may not, modulate the electrophysiological states of excitable cells, such as nociceptor neurons. Leishmania amazonensis (at concentrations of 1 × 10 6 ) can alter the electrical properties of the macrophage plasma membrane, inducing a hyperpolarization of the infected host cell membrane (Camacho et al. 2008; Forero et al. 1999; Quintana et al. 2010 ). As to whether Leishmania spp. can modulate the electrophysiological properties of the plasma membrane of nociceptor neurons is unknown. Such putative effects could contribute to an explanation of the clinical reports of hypoalgesia and the disturbances in temperature sensations, which have been described in CL patients (Kubba et al. 1987) .
Another relevant factor is the neuropeptide Y (NPY) levels, which changes in some tissues during the progression of experimental CL (L. major, 1 × 10 7 ), in both resistant and susceptible mouse strains versus non-infected controls (Mantyh et al. 1994) . NPY is a potent analgesic in models of inflammatory and neuropathic pain Ahmed et al. 1998; Intondi et al. 2008) . A reduced concentration of NPY is observed in the skin, secondary lymphoid organs, dorsal root ganglia, and spleen in both resistant and susceptible infected mouse strains. Reduced levels of NPY are primarily evident in the skin and draining lymph nodes of the BALB/c susceptible strain. In the skin, reduced NPY is only evident from week 6 post-infection (Mantyh et al. 1994) , suggesting that NPY participates in pain modulation in leishmaniasis (Mantyh et al. 1994) , with decreased NPY levels plausibly contributing to the hyperalgesia evident in BALB/c murine CL model (Kanaan et al. 2000; Karam et al. 2006 ). However, it still awaits investigation as to whether NPY plays a relevant role also in the physiopathology of human leishmaniasis.
Injections of low and high loads of parasites (L. major, 4 × 10 3 and 2.5 × 10 6 promastigotes, respectively) induce distinct hyperalgesic patterns in the course of experimental leishmaniasis, as evidenced in thermal hyperalgesia tests (hot plate and tail flick tests). Injection of low dose of L. major causes short-live hyperalgesia, until the 10th-15th day post-infection, but not edema. The injection of a high dose of L. major leads to sustained inflammatory hyperalgesia, until 8 weeks post-infection, as well as edema, until 20 weeks post-infection (Kanaan et al. 2000; Karam et al. 2006) . Even in early, low dose evoked hyperalgesia, increased levels of the hyperalgesic cytokines, IL-1β and IL-6, are present, accompanied by pain-related behaviors, which decrease gradually to control levels at days 6 and 4, respectively (Karam et al. 2006) . A role for IL-1β and IL-6 in this early L. major-induced hyperalgesia has been proposed, given that both are associated with a complex cascade of chemical mediators, including other cytokines, prostanoids, and sympathetic amines to induce the development and maintenance of inflammatory hyperalgesia (Cunha et al. 1991; Cunha et al. 1992; Cunha et al. 2005; Ferreira et al. 1988; Verri et al. 2006 ). However, a recent study using an experimental model of CL-induced pain, observed that TNF-α levels increase and correlate with peripheral hyperalgesia, as detected by the hot plate test. The β-blocker atenolol, but not the cyclooxygenase inhibitor, indomethacin, was efficient in reducing both TNF-α levels and hyperalgesia, without affecting IL-1β and KC levels, with KC levels being reduced only at the 7th day of infection. As such, a sympathetic regulation of TNF-α production mediates L. major-induced pain (Karam et al. 2016) . Therefore, it is likely that chronic L. major infection triggers a nociceptive cascade that is different from that caused by a carrageenan-induced non-infectious acute inflammatory stimulus, which increases TNF-α-dependent prostanoids production as well as the release of sympathetic amines . However, it is important to highlight that, to date, there has been no functional study targeting cytokines with antibodies, soluble receptors, receptor antagonists, or genetic deletion to modulate Leishmania infection-induced pain. As such, the cytokine role in the pathophysiology of Leishmania infectioninduced pain requires further investigation. Notably, neutrophils are the first leukocytes recruited to the dermal tissue after Leishmania inoculation (Kaye and Scott 2011; RibeiroGomes and Sacks 2012) . Neutrophil recruitment is the first response to many challenges, including the actual bite of the sandfly and parasite needle injection as well as the presence of the parasite in dermal tissue. Neutrophil recruitment is quickly observed following inoculations of L. amazonensis (BALB/c mice), L. major (C57BL/6 and BALB/c mice), and L. donovani (hamsters) in models of CL (Beil et al. 1992; Müller et al. 2001; Peters et al. 2008; Pompeu et al. 1991; Ribeiro-Gomes et al. 2007; Ribeiro-Gomes and Sacks 2012; Wilson et al. 1987) . The role of neutrophils in the development of post-incisional and inflammatory hyperalgesia has previously been proposed (Carrera et al. 2013; Cunha et al. 2008; Verri et al. 2009 ). Neutrophils are a well-recognized source of pro-hyperalgesic mediators including reactive oxygen species, cytokines such as TNF-α, IL-1β and IL-6, endothelin-1, leukotriene B 4 , and prostaglandin E 2 Guerrero et al. 2008; Ji et al. 2014; Mantovani et al. 2011; Verri et al. 2006; Verri et al. 2009 ). The release of all these mediators at the site of Leishmania inoculation, besides contributing to additional leukocyte recruitment and increased inflammation, may account for the sensitization of nociceptive neurons (Binshtok et al. 2008; Ferreira et al. 1988; Jin and Gereau 2006; Salvemini et al. 2011; Verri et al. 2006) . Therefore, the early recruitment and activation of neutrophils at the site of infection may be involved in the initial and/or persistent hyperalgesic response observed after Leishmania inoculation in experimental CL. However, at the moment, there are no studies targeting neutrophils in models of CL in regard to Leishmania infection-induced pain. An important issue in this context will be the separation of the neutrophil-related immune response, and the specific role of the neutrophil response in producing hyperalgesic molecules.
Cytokines such as IL-4, IL-10, and IL-13 have been described as potent anti-hyperalgesic molecules with efficacy in a number of inflammatory hyperalgesia models. Accordingly, their pharmacological inhibition or genetic deletion leads to increased inflammatory hyperalgesia (Borghi et al. 2015; Cunha et al. 1999; Poole et al. 1995; Shimizu et al. 2009; Üceyler et al. 2011; Vale et al. 2003) . Intraperitoneal injection of exogenous IL-10, in mice infected with L. major 4 × 10 , induce anti-hyperalgesic effects in mice models of CL by modulating the levels of cytokine production (Karam et al. 2011; Karam et al. 2007; Karam et al. 2013) . The withdrawal of the treatment with IL-10 or IL-13 re-establishes the hyperalgesia, as assessed by hot plate and tail flick tests, in L. major infected animals. IL-10 and IL-13 show differential effects on IL-6 and IL-1β production in the infected paws during these studies. IL-10 has no effect upon IL-6 levels (Karam et al. 2007 ), whilst IL-13 up-regulates IL-6 levels during L. major infection (Karam et al. 2011; Karam et al. 2013) . IL-10 treatment also reduces IL-1β levels, which gradually increase following the cessation of IL-10 administration during L. major infection (Karam et al. 2007 ). IL-13 treatment also reduces IL-1β levels in the early stages of the L. major infection. Unlike IL-10, the IL-13-induced reduction in IL-1β levels was still significant following the cessation of IL-13 administration, indicating that the modulation of IL-1β production by IL-13 may be more long lasting than IL-10, at least in this model of CL (Karam et al. 2007 ). Controversially, in rats, IL-13 has a hyperalgesic action, as seen in the hot plate test, as indicated by the early release of IL-1β followed by increased IL-12 in infected paw, during the course of the infection with L. major promastigotes, 2 × 10 6 (Haber et al. 2009 ). Both IL-1β and IL-12 are hyperalgesic cytokines (Ferreira et al. 1988; Verri et al. 2005) . The opposing results of IL-13 treatment of mice and rats in experimental CLinduced pain may be due to the components involved in the infection/inflammatory milieu, parasite strain, parasite load, and genetic background of the host (Haber et al. 2009 ).
Pain experienced after Leishmania spp. infection in humans
Leishmania infection induces cutaneous and mucocutaneous wounds in exposed areas of the body accessible to the sandflies forming non-ulcerative (nodulated) or ulcerative lesions, which leads to life-long scars, disfiguration, and severe disability (González et al. 2008; Nylén and Eidsmo 2012; Hartley et al. 2014) . These wounds vary considerably between clinical phenotypes of CL disease and there are at least three main phenotypes of CL: (i) localized cutaneous leishmaniasis, (ii) diffuse cutaneous leishmaniasis, and (iii) mucocutaneous leishmaniasis. Visceral leishmaniasis can induce a forth type of CL known as the post kala-azar dermal leishmaniasis (Nylén and Eidsmo 2012) . Images and micrographs of these cutaneous lesions can be found elsewhere (please see references of Nylén and Eidsmo 2012; Dantas et al. 2013; Viana et al. 2013; Handler et al. 2015a; Handler et al. 2015b; Hartley et al. 2014; Kevric et al. 2015; Almeida et al. 2016) .
Given that leishmaniasis wounds are usually painless, little attention is given to the cases reporting pain. Nevertheless, there is a growing body of cases indicating the presence of pain, which is reviewed below.
Peripheral neuropathic pain, as caused by a lesion or disease of the peripheral somatosensory nervous system (Finnerup et al. 2016) , is one of the most common neurological manifestations of visceral leishmaniasis (VL). The sensation of burning feet and hyperesthesia are the most common symptoms (Hashim et al. 1995; Llanos-Cuentas et al. 2013; Mustafa 1965 ). For instance, 13 patients with VL reported peripheral neuropathy (Mustafa 1965) , presenting with plantar hyperalgesia, calf tenderness, and vibration disturbance attributed to axonal degeneration and nerve demyelination. In support of this, a patient with CL caused by L. major infection reported initially with an itch followed by hyperesthesia in the lesion, which was related to the presence of the macrophages loaded with amastigotes around the perineural space (Satti et al. 1989) . Although, in this study, the patient did not show abnormalities in the peripheral nerves, the presence of hyperesthesia could be attributed to L. major (Satti et al. 1989) or L. donovani (Elhassan et al. 1992 ) being present in the perineural space and in Schwann cells, as reported in mice (Satti et al. 1989) . Importantly, the changes were reversed by specific treatment with anti-leishmanial drugs, with the presence of Leishmania spp. correlating with pain, itch, or hyperesthesia (Hashim et al. 1995; Llanos-Cuentas et al. 2013) . Another study of eight VL-infected Gulf War veterans with Leishmania tropica (Magill et al. 1993) showed seven out of eight reporting abdominal pain. Importantly, one of these patients reported abdominal pain as the primary symptom, with another patient spontaneously reporting pain without being questioned by the examiner, indicating the clinical relevance of pain symptoms to the patient (Magill et al. 1993) . The higher the parasite burden the greater the abdominal pain reported by VL patients (Silva et al. 2014) . In another case report, a patient with cutaneous, visceral, and ocular leishmaniasis, due to Leishmania braziliensis infection, reported generalized body and ocular pain (Gontijo et al. 2002) . Similarly, a patient with mucocutaneous leishmaniasis due to L. braziliensis infection presented with an ulcer, swelling, and pain in his right nostril (Weller et al. 2005) .
Interestingly, a patient developed painful erythematous target lesions on the palms and scapula together with conjunctivitis after a Leishmania skin test (LST) (Wind et al. 2014 ), linking to a clinical case study on a patient with a history of cutaneous ulcer and suspected leishmaniasis, where CL developed after LST (Machado et al. 2011) . Such clinical case studies indicate the importance of the immunological response, even to an inactivated Leishmania spp., in driving a pathophysiology with a CL-like disease course and pain.
In a study enrolling 736 patients diagnosed with CL, 61% of the patients reported itch and 38% reported pain (el-Safi et al. 1991) , again indicating that pain is an important symptom of human leishmaniasis. Furthermore, the pain reported by patients with L. donovani may be the result of inflammation in the peripheral nerves adjacent to lesions, given the presence of parasites in Schwanns cells and the perineural space (Elhassan et al. 1992; Llanos-Cuentas et al. 2013; Satti et al. 1989) . Alternatively, such pain may arise from an involvement of satellite lymphatics, leading to nerve compression (Llanos-Cuentas et al. 2013 ).
This compilation of data is summarized in Table 2 , with additional cases also shown. Such data clearly indicate that patients report generalized or focal pain upon infection with different Leishmania strains and with different leishmaniasis forms. (Shin et al. 2013) Leishmania (Leishmania) tropica Visceral 8 -Abdominal pain (7) (Magill et al. 1993) Leishmania (Viannia) braziliensis Cutaneous, visceral, and ocular 1 -Generalized and ocular pain (1) (Gontijo et al. 2002) Leishmania (Viannia) braziliensis Mucocutaneous 1 -Right nostril (1) (Weller et al. 2005) Not determined Mucocutaneous (laryngeal) 1 -Throat (1) (Moraes et al. 2012 ) Fig. 2 Scheme presenting the current understanding of peripheral mechanism of Leishmania (major)-induced pain in mice and rats. L. major inoculation (subcutaneously) causes an immunomodulatory reaction with increased production of known pro-hyperalgesic mediators such as TNF-α, IL-1β, IL-6, KC/CXCL1, and NGF. These mediators perpetuate the inflammatory process contributing to the maintenance of local edema. The persistent inflammation affects dermal perineural tissue leading to neuritis and possibly damage to the cutaneous nerves. This scenario sensitizes cutaneous sensory nociceptor neurons, which is parasitic burden-dependent given that high parasite doses induce long-lasting hyperalgesia whilst low doses induce short-lived hyperalgesia. The L. major-induced hyperalgesia is inhibited by IL-10, IL-13 (in the case of mice), thymulin, and the β-blocker atenolol; the effects of NPY and inhibition of neutrophils is still undetermined, and may represent promising therapeutic strategies in Leishmania-induced pain; COX non-selective inhibitors such as indomethacin have no effect in Leishmania-induced pain; and IL-13 enhances Leishmania-induced pain in rats, contrasting with the results in mice
Conclusions and future perspectives
In experimental rodent models, it is well-accepted that Leishmania induces pain. Figure 2 shows an integrated perspective of the current peripheral mechanism underpinning L. major-induced hyperalgesia in mice and rats. However, this scenario is not clearly observed in humans, despite the increasing number of reports of pain-related symptoms in patients diagnosed with leishmaniasis. It is reasonable to assume that in humans, both types of clinical scenarios may occur, with detected areas of pain as well as completely painless evolution of the disease. Such variations in nociceptive modulation seem dependent upon parasite strain, parasite load, type of leishmaniasis, time-course of disease, and the immune response of the patient. Further studies are necessary to better clarify the complex pathophysiology of pain in leishmaniasis. Although this issue has been already explored experimentally in the case of L. major, the mechanism(s) of action of other Leishmania species, both old and new world variants, in pain modulation requires further investigation. Hyperalgesia-related behaviors have primarily used thermal threshold assessment, such as hot plate and tail flick tests as well as a variation, as seen in the work of Cangussu et al. (2013) . It is important that the evaluation of Leishmania-induced hyperalgesia utilizes other methods, such as through cold stimulus, von Frey filaments, electronic pressure meter, or Randall & Selitto tests, given that these tests investigate different aspects of physiological changes associated with nociceptive signals (Cunha et al. 2004; Le Bars et al. 2001) .
The clinical reports of pain-related symptoms in human leishmaniasis, in different regions of the world, may indicate that pain can be independent of particular Leishmania species. It will be important to determine as to whether the pain reported correlates with the parasite burden. Furthermore, electrophysiological studies are essential to evaluate the influence of Leishmania spp. in the physiological properties of sensory neurons. Such investigations will provide additional information regarding the interaction between the Leishmania parasites and the mammalian host cells, and how such interactions modulate the presence or absence of pain signaling.
